Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes
Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved..
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome associated with high short-term mortality in patients with chronic liver disease. Chronic hepatitis B is the main cause of ACLF (HBV-ACLF) in China and other Asian countries. To improve disease management and survival for patients with ACLF, we aimed to discover novel biomarkers to enhance HBV-ACLF diagnosis and prognostication.
METHODS: We performed a metabolomics profiling of 1,024 plasma samples collected from patients with HBV-related chronic liver disease with acute exacerbation at hospital admission in a multi-year and multi-center prospective study (367 ACLF and 657 non-ACLF). The samples were randomly separated into equal halves as a discovery set and a validation set. We identified metabolites associated with 90-day mortality in the ACLF group and the progression to ACLF within 28 days in the non-ACLF group (pre-ACLF) using statistical analysis and machine learning. We developed diagnostic algorithms in the discovery set and used these to assess the findings in the validation set.
RESULTS: ACLF significantly altered the plasma metabolome, particularly in membrane lipid metabolism, steroid hormones, oxidative stress pathways, and energy metabolism. Numerous metabolites were significantly associated with 90-day mortality in the ACLF group and/or pre-ACLF in the non-ACLF group. We developed algorithms for the prediction of 90-day mortality in patients with ACLF (area under the curve 0.87 and 0.83 for the discovery set and validation set, respectively) and the diagnosis of pre-ACLF (area under the curve 0.94 and 0.88 for the discovery set and validation set, respectively). To translate our discoveries into practical clinical tests, we developed targeted assays using liquid chromatography-mass spectrometry.
CONCLUSIONS: Based on novel metabolite biomarkers, we established tests for HBV-related ACLF with higher accuracy than existing methods.
CLINICAL TRIAL NUMBER: NCT02457637 and NCT03641872.
IMPACT AND IMPLICATIONS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome associated with high short-term mortality affecting 25% of patients hospitalized with cirrhosis. Chronic hepatitis B is the main etiology of ACLF in China and other Asian counties. There is currently no effective therapy. Early diagnosis and accurate prognostication are critical for improving clinical outcomes in patients with ACLF. Based on novel metabolite biomarkers, we developed liquid chromatography-mass spectrometry tests with improved accuracy for the early diagnosis and prognostication of HBV-related ACLF. The liquid chromatography-mass spectrometry tests can be implemented in clinical labs and used by physicians to triage patients with HBV-related ACLF to ensure optimized clinical management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Journal of hepatology - 79(2023), 5 vom: 30. Nov., Seite 1159-1171 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical test development |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Print-Electronic ClinicalTrials.gov: NCT03641872, NCT02457637 Citation Status Publisher |
|---|
| doi: |
10.1016/j.jhep.2023.07.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360173136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360173136 | ||
| 003 | DE-627 | ||
| 005 | 20231226082440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2023.07.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360173136 | ||
| 035 | |a (NLM)37517452 | ||
| 035 | |a (PII)S0168-8278(23)04991-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03641872, NCT02457637 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome associated with high short-term mortality in patients with chronic liver disease. Chronic hepatitis B is the main cause of ACLF (HBV-ACLF) in China and other Asian countries. To improve disease management and survival for patients with ACLF, we aimed to discover novel biomarkers to enhance HBV-ACLF diagnosis and prognostication | ||
| 520 | |a METHODS: We performed a metabolomics profiling of 1,024 plasma samples collected from patients with HBV-related chronic liver disease with acute exacerbation at hospital admission in a multi-year and multi-center prospective study (367 ACLF and 657 non-ACLF). The samples were randomly separated into equal halves as a discovery set and a validation set. We identified metabolites associated with 90-day mortality in the ACLF group and the progression to ACLF within 28 days in the non-ACLF group (pre-ACLF) using statistical analysis and machine learning. We developed diagnostic algorithms in the discovery set and used these to assess the findings in the validation set | ||
| 520 | |a RESULTS: ACLF significantly altered the plasma metabolome, particularly in membrane lipid metabolism, steroid hormones, oxidative stress pathways, and energy metabolism. Numerous metabolites were significantly associated with 90-day mortality in the ACLF group and/or pre-ACLF in the non-ACLF group. We developed algorithms for the prediction of 90-day mortality in patients with ACLF (area under the curve 0.87 and 0.83 for the discovery set and validation set, respectively) and the diagnosis of pre-ACLF (area under the curve 0.94 and 0.88 for the discovery set and validation set, respectively). To translate our discoveries into practical clinical tests, we developed targeted assays using liquid chromatography-mass spectrometry | ||
| 520 | |a CONCLUSIONS: Based on novel metabolite biomarkers, we established tests for HBV-related ACLF with higher accuracy than existing methods | ||
| 520 | |a CLINICAL TRIAL NUMBER: NCT02457637 and NCT03641872 | ||
| 520 | |a IMPACT AND IMPLICATIONS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome associated with high short-term mortality affecting 25% of patients hospitalized with cirrhosis. Chronic hepatitis B is the main etiology of ACLF in China and other Asian counties. There is currently no effective therapy. Early diagnosis and accurate prognostication are critical for improving clinical outcomes in patients with ACLF. Based on novel metabolite biomarkers, we developed liquid chromatography-mass spectrometry tests with improved accuracy for the early diagnosis and prognostication of HBV-related ACLF. The liquid chromatography-mass spectrometry tests can be implemented in clinical labs and used by physicians to triage patients with HBV-related ACLF to ensure optimized clinical management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical test development | |
| 650 | 4 | |a diagnostic biomarkers | |
| 650 | 4 | |a prediction model | |
| 700 | 1 | |a Tan, Wenting |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xianbo |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Beiling |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Zhongji |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yanhang |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Zhiping |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Huadong |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yubao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Weituo |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Wenyi |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Guohong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Yixin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qun |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Shue |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Lihua |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ruochan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jinjun |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xiuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Sen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jinming |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Liujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Rongjiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Haotang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Xiaoliang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Lining |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hai |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hepatology |d 1993 |g 79(2023), 5 vom: 30. Nov., Seite 1159-1171 |w (DE-627)NLM012604372 |x 1600-0641 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g number:5 |g day:30 |g month:11 |g pages:1159-1171 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhep.2023.07.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |e 5 |b 30 |c 11 |h 1159-1171 | ||